IDH mutations occur frequently in Chinese glioma patients and predict longer survival but not response to concomitant chemoradiotherapy in anaplastic gliomas

Oncology Reports

Volumn 26, Issue 6, 2011, Pages 1479-1485

  Qi, Song Tao ^a   Yu, Lei ^a   Lu, Yun Tao ^a   Ou, Yang Hui ^a   Li, Zhi Yong ^a   Wu, Lan Xiao ^b   Yao, Fei ^b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b Helixgen (Guangzhou) Biotech Co Ltd   (China)

Author keywords

Chinese; Glioma; Isocitrate dehydrogenase 1; Isocitrate dehydrogenase 2; Prognosis

Indexed keywords

ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CHILD; CHINESE; CONTROLLED STUDY; FEMALE; GENE; GENE MUTATION; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; ISOCITRATE DEHYDROGENASE 1 GENE; ISOCITRATE DEHYDROGENASE 2 GENE; MAJOR CLINICAL STUDY; MALE; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PILOCYTIC ASTROCYTOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; CHILD; CHILD, PRESCHOOL; CHINA; FEMALE; GENETIC ASSOCIATION STUDIES; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION, MISSENSE; NEOPLASM GRADING; SEQUENCE ANALYSIS, DNA; TRANSITION TEMPERATURE; YOUNG ADULT;

EID: 80053508494     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1428     Document Type: Article

References (40)

1. Louis DN, Ohgaki H, Wiestler OD, etal: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109, 2007. (Pubitemid 47103521)
2. Stupp R, Mason WP, Van den Bent MJ, etal: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005. (Pubitemid 40349501)
3. Wen PY and Kesari S: Malignant gliomas in adults. N Engl J Med 359: 492-507, 2008.
4. Ohgaki H: Epidemiology of brain tumors. Methods Mol Biol 472: 323-342, 2009.
5. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, WenPY and Olson JJ: Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 60: 166-193, 2010.
6. Parsons DW, Jones S, Zhang X, etal: An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812, 2008.
7. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C and Von DeimlingA: Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116: 597-602, 2008.
8. Hartmann C, Meyer J, Balss J, etal: Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118: 469-474, 2009.
9. Ichimura K, Pearson DM, Kocialkowski S, etal: IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 11: 341-347, 2009.
10. Watanabe T, Nobusawa S, Kleihues P and Ohgaki H: IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174: 1149-1153, 2009.
11. Yan H, Parsons DW, Jin G, etal: IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 765-773, 2009.
12. Koshland DJ, Walsh K and LaPorte DC: Sensitivity of metabolic fluxes to covalent control. Curr Top Cell Regul 27: 13-22, 1985.
13. Sanson M, Marie Y, Paris S, etal: Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27: 4150-4154, 2009.
14. Dang L, White DW, Gross S, etal: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462: 739-744, 2009.
15. Ward PS, Patel J, Wise DR, etal: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17: 225-234, 2010.
16. Van den Bent MJ, Dubbink HJ, Marie Y, etal: IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 16: 1597-1604, 2010.
17. Wick W, Hartmann C, Engel C, etal: NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27: 5874-5880, 2009.
18. Dubbink HJ, Taal W, Van Marion R, etal: IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology 73: 1792-1795, 2009.
19. Houillier C, Wang X, Kaloshi G, etal: IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 75: 1560-1566, 2010.
20. Reed GH, Kent JO and Wittwer CT: High-resolution DNA melting analysis for simple and efficient molecular diagnostics. Pharmacogenomics 8: 597-608, 2007. (Pubitemid 46939585)
21. Macdonald DR, Cascino TL, Schold SJ and CairncrossJG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277-1280, 1990. (Pubitemid 20195640)
22. Brandsma D and Van den Bent MJ: Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol 22: 633-638, 2009.
23. Korshunov A, Meyer J, Capper D, etal: Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol 118: 401-405, 2009.
24. Horbinski C, Kofler J, Kelly LM, Murdoch GH and Nikiforova MN: Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues. J Neuropathol Exp Neurol 68: 1319-1325, 2009.
25. Bleeker FE, Lamba S, Leenstra S, etal: IDH1 mutations at residue p.R132 [IDH1(R132)] occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 30: 7-11, 2009.
26. Zou Y, Zeng Y, Zhang DF, Zou SH, Cheng YF and Yao YG: IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders. Biochem Biophys Res Commun 402: 378-383, 2010.
27. Dang L, Jin S and Su SM: IDH mutations in glioma and acute myeloid leukemia. Trends Mol Med 16: 387-397, 2010.
28. Yen KE, Bittinger MA, Su SM and Fantin VR: Cancer-associated IDH mutations: biomarker and therapeutic opportunities. Oncogene 29: 6409-6417, 2010.
29. De Carli E, Wang X and Puget S: IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 2248, 2249, 2009.
30. Pollack IF, Hamilton RL, Sobol RW, etal: IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children's Oncology Group. Childs Nerv Syst 27: 87-94, 2011.
31. Gravendeel LA, Kloosterhof NK, Bralten LB, etal: Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma. Hum Mutat 31: E1186-E1199, 2010.
32. Sonoda Y, Kumabe T, Nakamura T, etal: Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci 100: 1996-1998, 2009.
33. Hartmann C, Hentschel B, Wick W, etal: Patients with IDH1 wild-type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120: 707-718, 2010.
34. Nobusawa S, Watanabe T, Kleihues P and Ohgaki H: IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 15: 6002-6007, 2009.
35. Metellus P, Coulibaly B, Colin C, etal: Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol 120: 719-729, 2010.
36. Hegi ME, Diserens AC, Gorlia T, etal: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003, 2005. (Pubitemid 40349502)
37. Herrlinger U, Rieger J, Koch D, etal: Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J Clin Oncol 24: 4412-4417, 2006. (Pubitemid 46630979)
38. Weller M, Felsberg J, Hartmann C, etal: Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 27: 5743-5750, 2009.
39. Fu Y, Huang R, Du J, Yang R, An N and Liang A: Glioma-derived mutations in IDH: from mechanism to potential therapy. Biochem Biophys Res Commun 397: 127-130, 2010.
40. Yoshino A, Ogino A, Yachi K, etal: Gene expression profiling predicts response to temozolomide in malignant gliomas. Int J Oncol 36: 1367-1377, 2010.